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Abstract
Background: Our understanding of the molecular pathways that underlie melanoma remains incomplete. Although several
published microarray studies of clinical melanomas have provided valuable information, we found only limited concordance
between these studies. Therefore, we took an in vitro functional genomics approach to understand melanoma molecular
pathways.
Methodology/Principal Findings: Affymetrix microarray data were generated from A375 melanoma cells treated in vitro
with siRNAs against 45 transcription factors and signaling molecules. Analysis of this data using unsupervised hierarchical
clustering and Bayesian gene networks identified proliferation-association RNA clusters, which were co-ordinately expressed
across the A375 cells and also across melanomas from patients. The abundance in metastatic melanomas of these cellular
proliferation clusters and their putative upstream regulators was significantly associated with patient prognosis. An 8-gene
classifier derived from gene network hub genes correctly classified the prognosis of 23/26 metastatic melanoma patients in
a cross-validation study. Unlike the RNA clusters associated with cellular proliferation described above, co-ordinately
expressed RNA clusters associated with immune response were clearly identified across melanoma tumours from patients
but not across the siRNA-treated A375 cells, in which immune responses are not active. Three uncharacterised genes, which
the gene networks predicted to be upstream of apoptosis- or cellular proliferation-associated RNAs, were found to
significantly alter apoptosis and cell number when over-expressed in vitro.
Conclusions/Significance: This analysis identified co-expression of RNAs that encode functionally-related proteins, in
particular, proliferation-associated RNA clusters that are linked to melanoma patient prognosis. Our analysis suggests that
A375 cells in vitro may be valid models in which to study the gene expression modules that underlie some melanoma
biological processes (e.g., proliferation) but not others (e.g., immune response). The gene expression modules identified
here, and the RNAs predicted by Bayesian network inference to be upstream of these modules, are potential prognostic
biomarkers and drug targets.
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Introduction
Clinical aspects of melanoma
Malignant melanoma is a devastating form of cancer with a
particularly high incidence in New Zealand (NZ) and Australia
[1]. Although early-stage melanoma is curable, advanced
melanoma is very difficult to treat and is comparatively resistant
to chemotherapy. Very few agents (e.g. interferon-alpha2b) are
useful as adjuvant chemotherapy after primary tumours have been
excised. For disseminated melanoma there are currently only a
small number of chemotherapeutic agents in general use (e.g.
temozolomide and dacarbazine), which are not effective in all
patients [2]. Emerging approaches such as BRAF inhibition
(PLX4032, [3]) and immune-based therapies ([4–8]) hold great
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34247promise, but are unlikely to be effective for all melanoma patients.
We urgently need to improve our understanding of the complex
and variable molecular pathogenesis of melanoma, and based on
this understanding, develop biomarkers to allow better matching
of patients to therapeutic approaches. This study attempts to
address this challenge.
Melanoma molecular pathways
The molecular pathways that underlie melanoma are complex.
The roles of twenty-five molecules strongly associated with
malignant melanoma are summarised as briefly as possible below,
so that when functional genomic approaches based on mRNA
data are used later in this study, we can assess whether these
molecules and the molecular pathways they constitute are
identified.
Inherited mutations cause a genetic predisposition to melano-
ma, including mutations in cell cycle genes such as CDKN2A [9],
CDK4 [10], RB1 [11] and MDM2 [12], as well as melanocyte
differentiation and activation genes such as MC1R, TYR, TYRP1
and ASIP [13]. Somatic mutations in other genes are thought to
play a role in disease progression. For example, phosphatidylino-
sitol 3-kinases (PI3K) and their downstream targets of the protein
kinase B (Akt) family are constitutively activated in many
melanomas [14]. The gene encoding the phosphatase PTEN is
also commonly mutated in melanoma [15], which reduces PTEN’s
ability to dephosphorylate phosphoinositides and to inhibit PI3K-
Akt signalling pathways, and therefore increases proliferation and
decreases apoptosis [16].
Other molecules commonly involved in melanoma progression
include NRAS[17] and BRAF [18,19], which appear to occur in
mutually exclusive sets of tumours [20] and lead to constitutively
active MEK–ERK signalling. This causes up-regulation of p38/
Jun N-terminal kinase (JNK) activity and activation of c-Jun,
which promotes the transcription of Jun targets including MMP2,
RACK1 and CCND1 [21]. Constitutively active MEK–ERK
signalling also causes phosphorylation and activation of the
transcription factor MITF [22], which promotes the expression
of its target genes including BCL2, CDKN1A, TYR, TBX2 and
CDK2 [23,24]. MITF expression is also promoted by transcription
factors such as Pax3 and Sox10 [25] and inhibited by the
transcription factor BRN2 [26]. The overall expression of MITF in
melanoma is associated with clinical outcome [27], however,
melanomas are heterogeneous, appearing to contain individual
cells with different phenotypic and gene expression patterns [28].
When MITF expression in melanomas is examined on a cell by cell
basis, the slow-growing stem-cell-like melanoma-initiating cell
population appears to have low MITF expression, and in accord
with this, inhibition of MITF in B16 mouse melanomas reduces
proliferation and up-regulates the stem cell marker Oct4 [29]. It
appears that the BRAF and MITF signalling pathways described
above synergise to give melanoma cells their neoplastic, and later
their invasive and metastatic, phenotypes. For example, p16
INK4
inactivation and BRAF mutation can accompany MITF amplifi-
cation in melanoma cell lines, and ectopic MITF expression
appears to work in synergy with BRAF mutation to transform
primary human melanocytes [30].
Inferring molecular pathway activity from gene
expression data
Melanoma research was one of the earliest fields in which
expression profiling was applied to tumour classification [31].
RNAs over-expressed in melanoma have been used to predict
melanoma invasiveness, metastasis, prognosis and immunotherapy
response, and are thought to represent transcriptional signatures of
some of the melanoma molecular pathways described above [32–
36]. The abundance of RNAs encoding proteins that are targets of
the same transcription factors [37] or that function within the
same molecular pathways [38] are sometimes correlated in an
evolutionarily conserved and tissue-specific manner [39,40].
Therefore the activity of signalling pathways may potentially be
inferred from the abundance and correlation of those RNAs
known to be transcribed when the pathways are active [41,42].
This principle has been used to identify molecular pathways
associated with the transformation of melanocytes into melanomas
[43], and contributes to in silico models of gene-to-gene
relationships known as gene networks [44]. In a gene network, a
connection between two RNAs (sometimes referred to as an
‘‘edge’’) implies either co-expression of the two RNAs or the
regulation of the abundance of one RNA by the abundance of the
other, either directly or via intervening signalling molecules and
transcription factors. In gene networks RNAs are usually referred
to as ‘‘nodes’’, connections between them referred to as ‘‘edges’’
and groups of RNAs that are highly correlated with one other are
referred to as ‘‘clusters’’. There are several types of gene networks
that model RNA-to-RNA relationships using different assump-
tions, ranging from simple non-directional correlation-based
methods [39], sometimes referred to as relevance networks, to
complex Bayesian gene networks, which can model directional
and synergistic relationships between molecules [45,46]. Until
recently, due to computational limitations, most directional gene
network methods could only model interactions between a few
hundred genes at a time. However, in 2010, a method to identify
whole-genome-scale Bayesian gene networks using massively
parallel supercomputers was developed [47], which is used in this
study.
Combination of cell line and tumour gene expression
data in this study to understand melanoma pathways
In this study we find that the association of tumour clinical
features with either individual RNAs or inferred molecular
pathway activity is not consistent across published melanoma
microarray datasets. Given this lack of consistency, and the
consequent difficulty of using data from the diverse melanomas of
patients to understand melanoma molecular pathways, we instead
take an in vitro functional genomic approach. We generate
microarray data from the melanoma cell line A375 exposed to a
set of targeted siRNA disruptions, and used these data to identify
co-expressed clusters of genes that are strongly conserved between
siRNA-treated A375 cells and melanomas from patients. Several
of these individual clusters encode proteins with shared cellular
functions; we show that those clusters related predominantly to
cellular proliferation are significantly associated with the prognosis
of metastatic melanoma patients.
Results
Published melanoma studies fail to identify consistent
gene or molecular pathway signatures
In several individual published microarray studies of melanomas
from patients, sets of genes appear to be differentially expressed in
association with three aspects of tumour biology: progression,
metastasis and prognosis. We wished to assess whether the genes
associated with these clinical features were consistent across the
multiple published studies. Therefore, the raw data from several
well-designed microarray studies that addressed progression, metas-
tasis and prognosis were retrieved (Table 1). Quality control
assessment indicated that all data was of acceptable quality and
re-analysis of each dataset from Table 1 identified sets of
Gene Networks Associated with Melanoma Prognosis
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lished, although the different studies appeared to vary widely in
their statistical power. However, a statistical meta-analysis using
the R ‘metaMA’ package with false discovery rate controlled to
#5% [48] was unable to identify any sets of RNAs consistently
associated with progression, metastasis or prognosis. Venn diagrams are
shown in Figure 1 to illustrate the relative lack of consistency
between RNAs differentially expressed in the various studies.
We then used pathway level analysis to analyse the differential
expression of functionally-linked gene sets associated with
melanoma progression, metastasis and prognosis. The Gene Annotation
Tool to Help Explain Relationships (GATHER) [49] and Principal
Coordinates and Hotelling’s T2 (PCOT2) [42] applications failed to
find any TRANSFACPro [50], Gene Ontology (GO) [51], or
Kyoto Encyclopaedia of Genes and Genome (KEGG) [52] gene
sets that were consistently differentially expressed in more than
one study of melanoma prognosis or progression. GATHER analysis
only identified two gene sets consistently differentially expressed in
the studies of metastasis (G-protein coupled receptor signalling,
GO.0007186 and epidermis development, GO.0008544; Bayes
Factor $5, p#0.05). In summary, our analysis of published
melanoma microarray studies addressing tumour progression,
metastasis and prognosis identified little concordance between the
different studies at the levels of individual RNAs or gene sets.
Generation of a microarray dataset using siRNA
knockdowns in cultured A375 melanoma cells
Given the lack of consistent RNA signatures for melanoma
progression, metastasis and prognosis from microarray studies of
melanomas from patients, and the consequent difficulty of using
data from the diverse melanomas of patients to understand
melanoma molecular pathways, we took an in vitro functional
genomics approach. This involved multiple siRNA knockdown
experiments in the A375 melanoma cell line, in which the
abundance of specific target mRNAs were reduced in separate
cultures of melanoma cells before Affymetrix U133plus2 micro-
array analysis. The principle of this study was that each siRNA
experiment would alter the activity of a subset of signalling
pathways and consequently the abundance of mRNAs down-
stream of those pathways, allowing clustering and gene network
analysis to identify the strongest statistical relationships between
any of the 54,000 probe sets, across the siRNA-treated cells. We
selected 45 siRNAs (Table 2) that targeted molecules known to be
important in melanoma cell biology and were able to produce $2
fold reduction in the abundance of their target mRNAs.
Additional selection criteria were: (i) that the target molecules
were recorded in the Ingenuity Pathways Analysis (IPA) systems
biology database (http://www.ingenuity.com/) to influence the
expression of $50 downstream mRNAs, and (ii) they were
relatively abundant in A375 cells (on average $50
th percentile of
abundance in the microarray data). RNA from A375 cultures
transfected with these 45 siRNAs, along with control inactive
fluorescently-labelled siRNAs, were analysed using Affymetrix
microarrays. The distribution of target ‘knock-down’ efficacy is
shown in Figure 2.
Identification of biologically-relevant clusters in the A375
microarray dataset using unsupervised methods that
make no prior assumptions about cluster membership
To explore whether this A375 dataset contained biologically
sensible information, we first attempted to identify biologically
relevant clusters of RNAs that were correlated across the A375
siRNA microarray dataset. As discussed in the introduction, we
would expect mRNA targets of transcription factors [37] or
mRNAs encoding proteins of common function [53] to be more
highly correlated than expected due to chance. Hierarchical
clustering was performed in R using Ward’s method and the
dendrogram cut to identify 200 clusters of probe sets (see
Methods). Each cluster was then analysed using the GATHER
web tool accessed through an R script to identify any GO or
TRANSFAC gene sets for which clusters were significantly
enriched. 66 clusters with at least one enriched gene set were
identified; eight of these were significantly enriched for the targets
of specific transcription factors (Table 3) and five were significantly
enriched for cell cycle-associated GO gene sets (GO paths
GO:0007049 {3 clusters} and GO:0008283 {2 clusters}). GO
paths for which other clusters were enriched included: DNA
recombination (GO:0006310), transcription (GO:0006350), pro-
tein folding (GO:0006457), intracellular apoptosis induction
(GO:0008629) and regulation of phosphorylation (GO:0042325).
Similar results were obtained when we identified stably observed
clusters using bootstrap resampling through the ‘pvclust’ R
package; we found 134 clusters with ‘approximately unbiased’ p-
values $0.95, 51 of which had at least one enriched GO path; of
these seven had functional enrichment for cellular proliferation.
In one particular cluster, 61 of 67 RNAs were targets of the cell
cycle-associated transcription factor E2F1. This is shown by
plotting heatmaps of Spearman’s correlation coefficient (r) and
Figure 1. Intersection between gene signatures identified by microarray studies of melanoma tumour prognosis, metastasis and
invasion. (A). The intersection between RNAs identified in four studies of prognosis ([78];[79];[56];[57]). (B). The intersection between RNAs identified
in four studies of metastasis ([56];[28];[54];[55]). (C) The intersection between RNAs identified in three studies of invasion ([80];[81]; [82]).
doi:10.1371/journal.pone.0034247.g001
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cluster were also correlated (or negatively correlated) with the
RNAs encoding the E2F family members themselves (which were
also part of the cluster, and are arrowed in Figure 3A). This cluster
is also significantly enriched for genes that encode members of the
cell cycle-associated GO gene set GO:0007049.
To evaluate the potential clinical relevance of these clusters, we
assessed whether the RNAs we identified as co-expressed across
the A375 siRNA microarray data were also co-expressed across
microarray data from primary and metastatic melanomas from
patients. A composite Affymetrix U133A microarray dataset from
primary melanomas using three published studies [54–56], and a
separate composite Affymetrix U133A dataset from metastatic
melanomas using four published studies [54–57] were assembled
and normalised from raw data by the RMA method. Ward’s
method hierarchical clustering using the Agnes function in R with
either: (i) all probe sets or (ii) only those probe sets with median
signals $1.5x the 39 BioB probe set (i.e. well above the level of
noise in the microarrays) suggested that the A375 cell data lay
approximately equidistant between the primary and metastatic
melanoma data sets, which were more similar to one another than
they were to the A375 cell data (data not shown). Using the probe
sets from the A375 cell cluster that is shown in Figure 3, we
calculated Spearman’s r across both the primary and the
metastatic tumour microarray data (Figure 4 A and B,
respectively). As a control, Spearman’s r was also calculated
across the tumour data for equally sized but randomly chosen
RNA sets (Figure 4C–D). For these randomly chosen RNA sets
relatively few RNAs were seen to correlate highly with one another
(Figure 4E–F). Similar results were found for clusters enriched for
SOX9, FOXO4 and MAZ targets. For these gene sets, in primary
melanoma data 43%, 32% and 39% of possible probe set pairs,
respectively, had Spearman’s r$0.6. In metastatic melanoma data
Table 1. Gene signatures from multiple microarray studies of melanomas from patients.
Author Melanoma samples
Prognostic
signatures
Progression
signatures
Metastatic
signatures Reference
Winnepenninckx et al. primary melanoma ++ [58]
Mandruzzato et al. metastatic melanoma + [78]
Riker et al. (GSE7553) primary vs. mixed
metastatic
+ [55]
Jaeger et al. primary vs. cutaneous metastatic + [54]
Haqq et al. primary vs. mixed
metastatic
++ [83]
John et al. lymph node metastases + [79]
Xu et al. (GSE8401) melanoma tumours ++ [56]
Pfaff-Smith et al. primary vs. mixed
metastatic
++ [80]
Jeffs et al. melanoma cell lines + [82]
Hoek et al. melanoma primary
cultures
+ [28]
Talantov et al. normal skin vs nevus vs primary
melanoma
+ [81]
Bogunovic et al. metastatic melanoma + [57]
The table summarises melanoma prognostic, progression and metastatic gene signatures that have been generated from a set of high-quality published microarray
studies.
+indicates that the array study generated the corresponding type of signature.
doi:10.1371/journal.pone.0034247.t001
Figure 2. Frequency distribution of % ‘knock-down’ of target mRNA abundance. X-axis represents the percentage knock down in mRNA
target abundance that was induced by the specific siRNA, as reported by microarrays (calculated based on mRNA abundance in the siRNA-targeted
array/median mRNA abundance in all other arrays). The left y-axis represents the frequency of knockdown for each of the x-axis bins (blue bars) and
the right y-axis represents the cumulative frequency (pink line).
doi:10.1371/journal.pone.0034247.g002
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OGS
degree of target knockdown (relative to the
median array)
% reduction in
expression Batch
ABL1 22.01 50% KD2
AKT1 22.79 64% KD2
CCNA2 22.87 65% KD2
CCNB1 22.84 65% KD2
CCNB2 23.96 75% KD3
CCND3 22.91 66% KD2
CDC16 22.98 66% KD2
CDC2 22.72 63% KD1
CDC25B 22.08 52% KD1
CDC37 22.17 54% KD2
CDK2 22.6 62% KD2
CDK4 23.42 71% KD2
CDK7 22.53 60% KD1
CDKN2C 22.37 58% KD2
CEBPD 22.02 50% KD2
CEBPZ 22.96 66% KD2
CHEK1 22.8 64% KD2
CTNNB1 22.19 54% KD1
ETS1 21.98 49% KD3
FOXM1 22.69 63% KD2
FOXO3A 22.72 63% KD1
GABARAP 23.6 72% KD2
HDAC2 22.84 65% KD2
HDAC3 22.77 64% KD2
HSF2 24.62 78% KD1
MAP2K1 23.44 71% KD2
MAPK1 22.05 51% KD2
MCM2 25.96 83% KD3
MITF 214.51 93% KD3
NCOR2 22.32 57% KD2
NMI 24.77 79% KD2
PCNA 22.7 63% KD1
PIAS1 23.04 67% KD3
PIK3CB 22.15 53% KD2
RB1 24.34 77% KD1
RBL2 22.53 60% KD2
RELA 22 50% KD2
SKP2 23.4 71% KD2
SP1 21.99 50% KD3
SP100 23.06 67% KD2
STAT1 23.29 70% KD2
STAT3 25.75 83% KD3
STAT6 22.21 55% KD2
TCEA1 23.04 67% KD1
TP53 22.74 64% KD1
‘OGS’ designates the official gene symbol of the target mRNA, ‘Degree of knockdown’ is the fold reduction in expression of the target RNA after siRNA incubation
relative to median expression of the target RNA in all microarrays, ‘% reduction in expression’ is the % that the target RNA expression is reduced relative to median
expression of the target RNA in all other microarrays, and ‘Batch’ is the experimental batch in which the siRNA was used.
doi:10.1371/journal.pone.0034247.t002
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Spearman’s r$0.6.
In summary, unsupervised clustering of microarray data from
siRNA-treated A375 cells identified RNA clusters that encoded
proteins with common functional annotations, as well as RNA
clusters that shared common transcription factor binding motifs in
their gene promoters. We showed that members of four of these
A375 cell-derived clusters were also correlated in both primary
and metastatic melanomas, suggesting that the A375 microarray
dataset did indeed contain ‘biologically sensible’ and clinically
valid information.
Systematic analysis in the A375 data of gene sets
associated with specific transcription factors or biological
functions
We then screened pre-defined gene sets that shared common
transcription factor promoter motifs (based on the TRANSFAC
Pro database) or functional annotations (based on the GO
database) for high correlations in any of: (i) the siRNA-treated
A375 dataset, (ii) primary melanomas, and (iii) metastatic
melanomas. Gene sets with high correlations between their
constituent RNAs in both the A375 and clinical melanoma data
may represent cases where the siRNA-treated A375 data can
provide a valid model for gene regulatory processes that occur in
the melanomas of patients. Conversely, gene sets with high
correlations between their constituent RNAs in clinical melanoma
microarray data but not in the A375 data may represent cases
where clinically important RNA clusters are not adequately
modelled by our siRNA-treated A375 cells.
All possible gene sets with $5 members were retrieved from: (i)
the TRANSFAC Pro v 8.2 database (356 gene sets, each
containing genes with a common transcription factor binding
motif in their promoters) and (ii) the GO v 1.81 database (1,229
gene sets, each encoding proteins with common function). For
each TRANSFAC and GO gene set, using each of the three
microarray datasets, we used an R script to calculate the fraction
of gene pairs that correlated so that the absolute value of
Spearman’s correlation coefficients (|r|) was $0.5. We found that
several gene sets had a similar, albeit relatively low, frequency of
correlated gene pairs in all three of the A375, primary and
metastatic melanoma datasets – e.g. E2F1, PAX3, CREBP, cell
cycle and DNA repair gene sets (Figure 5). We also found gene sets
with members that were more frequently correlated across
tumours than across the A375 microarray data. These included
immune response, heparin sulphate proteoglycan synthesis, amino
acid acetylation, MYC/MAX, POU3F2 and GCNF gene sets
(Figure 5). Interestingly, a GO gene set associated with death
receptor-induced apoptosis was more frequently correlated in the
A375 microarray than in primary or metastatic tumours (Figure 5).
In summary, we identified several gene sets, including gene sets
associated with the cell cycle, that had similar frequencies of
correlation in both siRNA-treated A375 cells and in melanomas
from patients. These may represent active transcriptional
pathways regulating biological processes that occur in melanomas
and appear to be effectively modelled in siRNA-treated A375 cells
in vitro. However, transcriptional pathways underlying some other
processes such as immune response appear to be identified across
the melanoma tumours (in which complex tumour cell-leukocyte
interactions occur) but are not apparent in the microarray data
from A375 cells cultured in the laboratory.
Bayesian gene network analysis
In order to predict more complex RNA-to-RNA relationships in
the siRNA-treated A375 cells, including upstream regulators of the
co-expressed clusters described above, and the putative direction
of RNA-to-RNA relationships, we analysed the A375 cell
microarray data using a whole-genome Bayesian gene network
inference method [47], which identified 1,645,882 edges (can be
downloaded, with a brief explanatory file, from http://www.
bioinformatics.auckland.ac.nz/doc/project_data/Supplementary_
FIle_1.txt).
As described in the introduction, gene network nodes with large
numbers of downstream ‘‘children’’ are putative master-regulators
of biological processes, and are often known as ‘‘hubs’’. 11 of the
Table 3. Enrichment of transcription factor targets in A375 clusters.
Cluster TRANSFAC Annotation
Number of RNAs in
cluster
with annotation
ln Bayes
factor
probability of obtaining $
this Bayes factor by
chance
9 V$CDC5_01: cell division control protein 5 65 5.37 0.01
9 V$E2F1_Q6: E2F-1 61 6.51 0.01
79 V$SOX5_01: Sox-5 32 7.62 0
79 V$SOX9_B1: SOX (SRY-related HMG box) 35 6.46 0.01
101 V$KROX_Q6 61 10.56 0
101 V$MAZ_Q6 71 5.84 0
101 V$MAZR_01: MAZ related factor 50 4.27 0.02
113 V$CMYB_01: c-Myb 9 6 0.04
246 V$YY1_02: Yin and Yang 1 13 5.31 0.05
266 V$FOXO4_01: fork head box O4 24 5.11 0.02
282 V$WHN_B: winged-helix factor nude 10 6.49 0.03
283 V$OCT1_02: octamer factor 1 13 7.29 0.01
358 V$NRF1_Q6 5 6.27 0.04
The first column is the cluster identifier. The second column is the enriched TRANSFAC Pro v8.2 transcription factor motif in the promoter of the genes in the cluster. The
third column is the numbers of RNAs with the transcription factor target annotation in the cluster. The fourth and fifth columns are from the GATHER web tool –
indicating the Bayes factor and the permutation p-value for the Bayes factor (indicating how often $ this Bayes Factor may be expected due to chance), respectively.
doi:10.1371/journal.pone.0034247.t003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34247Figure 3. Heatmaps illustrating relationships across data from A375 cells treated with siRNAs in vitro between members of a cluster
of mRNAs found to be enriched for an E2F1 promoter motif. (A) Heatmap illustrating Spearman’s correlations within the cluster. The colour
key at the top left maps Spearman’s correlation coefficients between probe sets to colour, note that the range of r is +0.4 to +1. Probe sets encoding
E2F-family proteins are indicated by arrows. (B) Heatmap illustrating expression values of probe sets in this cluster (rows) in the A375 siRNA
knockdown arrays (columns), the colour key at the top left maps Z-transformed expression values to heatmap colours.
doi:10.1371/journal.pone.0034247.g003
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melanoma pathogenesis were identified as hubs in the Bayesian
gene network: SOX10, CCND1, RB1, and BCL2 all had over 50
children, while PTEN, TYR, CDKN2A, BRAF, PAX3, AKT1 and
MITF had between 30 and 50 children. In line with the clustering
analysis described above, several members of the E2F transcription
factor family were hubs in the gene network, with E2F4
(38707_r_at), E2F7 (241725_at), and E2F1 (2028_s_at) having
181, 103 and 43 network children, respectively. Reassuringly, 226
of the 327 combined children of these three E2F transcription
factors have E2F binding sites in their promoters, a significantly
greater proportion than would be expected due to chance
(empirical p#0.05). As well as identifying hubs, Bayesian gene
networks also identify clusters of co-expressed RNAs, which are
downstream of the same hub. Identifying these clusters may be
seen as a more conservative use of this network method than
identifying directional edges, and is the primary use made of
Bayesian gene networks in this paper. Reassuringly, every one of
the 200 clusters identified by the hierarchical clustering method
above had at least 70% of their members included among clusters
identified by the gene network method.
Figure 4. RNAs that are correlated in an E2F1-associated A375 cell-derived cluster are also correlated in datasets of primary and
metastatic melanomas. A and B show heatmaps of Spearman’s correlation coefficients between the E2F1 cluster probe sets shown in Figure 3,
across primary and metastatic melanoma data. C and D show heatmaps of Spearman’s correlation coefficients between members of a random list of
probe sets the same size as the E2F cluster used in panels A and B, across primary and metastatic melanoma datasets. E and F show in red kernel
density plots of the correlations shown in A and B, respectively. In grey they show Spearman’s correlations across primary and metastatic melanoma
datasets, respectively, between 10 random list of probe sets the same size as the E2F cluster. The colour key at the top left of each heatmap maps
Spearman’s correlation coefficient between probe sets to colour. The deepest red colour represents the Spearman’s correlation coefficient of 21 and
the deepest green colour Spearman’s correlation coefficient of 1. Note that, in order to illustrate the broad range of correlations observed, the scale
used here is different from that used in Figure 3.
doi:10.1371/journal.pone.0034247.g004
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with melanoma patient survival?
We wished to determine whether the Bayesian gene network
hubs and clusters identified from the A375 microarray data were
associated with prognosis. Therefore, we used the ‘Survival’
package in R to generate Cox proportional Hazards models to
estimate the association between the abundance of RNAs in
tumours and the survival of melanoma patients. Two survival
models were generated: (i) based on gene expression in metastatic
melanomas using an Affymetrix microarray dataset [57] and (ii)
based on gene expression in primary melanomas using an Agilent
microarray dataset [58], which was mapped to Affymetrix probe
IDs using Entrez gene ID annotations. We then used this
melanoma microarray survival information to assess whether gene
network hubs and clusters were significantly associated with
patient survival.
Firstly, to establish a baseline, we considered whether the
abundance of RNAs that encoded proteins with particular classes
of functional annotation were significantly associated with patient
survival. We hypothesised that RNAs encoding the types of
proteins that perform important oncogenic functions (e.g.
invasion, DNA replication, or immune response) may be more
strongly associated with the survival of patients than the
abundance of RNAs that encode proteins that do not play known
roles in cancer. For both primary tumours (the Winnepenninckx et
al., 2006 dataset [58], Figure 6A) and metastatic tumours (the
Bogunovic et al., 2009 dataset [57], Figure 6B), no one functional
category was clearly more or less associated with patient survival
than all RNAs taken together. This analysis was repeated for all
Bayesian gene network hubs with $50 downstream children but
again it did not identify any particular functional category with
strong patient survival associations (data not shown).
We then repeated this analysis focussing on hubs with children that
encoded proteins of common function. We used the GATHER web tool
to identify hubs with children significantly (Bayes Factor $5 and
p#0.05) enriched for GO paths. We found that 204 hubs had
children significantly enriched for one of 60 GO paths, which
covered a broad range of functions including transcription,
metabolism, signal transduction, stress response, DNA repair,
and cellular proliferation. Box plots were used to visualise the
strength of association between the expression of these hub
mRNAs in primary (Figure 6C) and metastatic (Figure 6D)
melanomas and patient survival. Functional enrichment of
children had little influence on the strength of association between
hub mRNA abundance and patient survival in the Winnepen-
ninckx et al. primary tumour dataset (Figure 6C), however, it
appeared to have a strong influence on the strength of association
between hub abundance and patient survival in the Bogunovic et
al. metastatic tumour dataset (Figure 6D). For example, 64% of the
hubs that had their children enriched for cell cycle regulation
functions had statistically significant associations with patient
survival. Interestingly, in all cases where hubs had children
enriched for cell cycle functions, the hub itself also encoded a
protein with cell cycle function. Conceivably, by providing a
summary of the abundance of their cell cycle-related co-expressed
children, these hubs may in effect be quantifying the activity of cell
cycle pathways in metastatic melanoma tumours.
The hubs with children enriched for cell cycle functions
included: MCM5 (initiation of DNA replication – this cluster has
73% intersection with the E2F1-associated cluster identified by
simple clustering analysis and shown in Figure 3), TYMS, DTL,
CENPU, PRIM1, MELK1 and PBK (PDZ binding kinase, a serine/
threonine kinase). All hubs with children enriched for various GO
paths related to cell cycle, mitosis or proliferation with Bayes
Factor $5 and p#0.05 are shown in Table S1. Displaying the
edges between the cell cycle-associated hubs and their children as
a directed graph using the Cytoscape application showed that
most of the cell cycle-associated clusters were relatively indepen-
dent of one another, although some were extensively interlinked
(Figure 7).
Figure 5. Correlations within functionally-related gene sets in A375 cells and melanomas. All possible gene-gene correlations within
gene sets defined by TRANSFAC and GO were calculated. The proportion of the gene pairs within each gene set that had Spearman’s |r|$0.5 was
calculated separately for A375 siRNA microarray data (blue bars), a composite Affymetrix dataset from three primary melanoma studies (red bars), and
a composite Affymetrix dataset from four metastatic melanoma studies (green bars). The x-axis represents TRANSFAC or GO gene sets. The y-axis
represents the proportion of gene pairs from each gene set that had Spearman’s |r|$0.5 for the A375 data, primary tumour data, and metastatic
tumour data, respectively.
doi:10.1371/journal.pone.0034247.g005
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34247Figure 6. Association between melanoma patient survival and the abundance of RNAs identified as gene network hubs that have
their gene network children enriched for specific GO annotation categories. The x-axes represent GO annotations. GO annotations with
related functions are coloured and grouped together: red (cell cycle related); sky blue (DNA repair related); green (RNA related); purple (transcription
related); dark blue (metabolism related); yellow (protein related) and grey (miscellaneous). The left-most box (white) in each panel represents all RNAs
on the microarray. The y-axes represents minus logbase2 p value, based on a Cox proportional hazards model, to indicate the strength of association
between RNA abundance and patient survival. The horizontal line (y=4.32) represents a threshold for a significant association with survival
(equivalent to p=0.05, above this line is a significant association). Within each box the dark horizontal line represents the median, the coloured area
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cycle-associated clusters are potentially clinically relevant, since
hub RNA-to-child RNA correlations were found in both the A375
and metastatic tumour (Bogunovic [57]) data set. For example, 16
of the A375 data-derived network hubs with cell cycle-enriched
children also had Spearman’s correlations of |r|$0.4 with $10 of
their children across the tumours in the Bogunovic clinical
melanoma data set (Table S2). As an example, the Spearman’s
correlations in the A375 and Bogunovic datasets between the hub
DTL and its gene network children are listed in Table S3.
Gene network hubs used to classify melanoma patient
outcome
Given that a subset of the A375 gene network hubs appeared to
be clinically relevant molecules, we used those 181 gene network
hubs with $50 children and with an association with metastatic
melanoma patient survival of p#0.005 to construct a classifier for
patient survival. This was done using metastatic melanoma
microarray data [57], after separating tumours into two classes:
(i) tumours from patients who died before 2 yrs (n=10), and (ii)
tumours from patients who lived beyond 3yrs (n=16). Shrunken
centroid classifiers were developed use the PAMR method [59],
and cross-validation suggested the optimal classification was
obtained using eight of the gene network hub RNAs (Figure S1A).
This analysis allowed 85% (12/16) of patients alive after 3 yrs to
be correctly classified, and 90% (9/10) of patients dead before
2 yrs to be correctly classified in a cross-validation experiment.
Expression patterns for the eight RNAs relative to the patient
classes are shown in Figure S1B.
In summary, Bayesian gene network analysis of the A375
microarray data identified hubs with children enriched for
numerous biological functions. In metastatic melanomas, gene
network hubs with downstream children enriched for cell cycle
functions are strongly associated with patient prognosis. Hence
these hubs are candidate biomarkers for cell cycle activity and
patient prognosis. Additional candidates as prognostic markers
were identified in a pilot class prediction experiment.
Laboratory investigation of Bayesian gene network hubs
While many of the Bayesian gene network hubs are already well
known in cancer biology, some hubs represented molecules that
had not been well characterised in terms of their role in cancer
cells. We subjectively selected three poorly characterised hubs for
further study – all had sets of child RNAs that were significantly
enriched (GATHER Bayes Factor $5 and p#0.05) for functions
that were easy to assess in the laboratory: (i) ELMOD1 (231930_at)
has only 8 gene network children, however all encode proteins
associated with programmed cell death (GO:0012501 – MARK4,
NGFRAP1, PIK3R2, PRKCA, PRSS23, SEPT4, TIA1, and TUBB4).
(ii) TMCO1 (210768_x_at) has 92 network children, a significant
subset of which encode proteins associated with the GO
annotation of apoptosis (GO:0006915 – e.g. BIT1, CRADD,
EBAG9, NOL3, PSEN2, SPATA4 and SPIN2), and (iii) UBE2S
(202779_s_at) has 67 network children, a significant subset of
which encode proteins associated with the cell cycle (GO:0007049
– e.g. AURKB, BUB3, CCNF, CDK5RAP1, CHAF1B, CHEK2,
GTSE1, KIF22, KIFC1, MAD2L1, RAD54L, RFC5, RNASEH2A,
RPA1 and RPA3) and DNA damage response/repair
(GO:0006974 – e.g. CHAF1B, CHEK2, DDB2, GTSE1, KIF22,
NEIL3, RAD54L, RFC5, RPA1 and RPA3).
The coding regions of ELMOD1, TMCO1 and UBE2S were
amplified by proof-reading PCR from an A375 cell cDNA
template and ligated into the pcDNA3.3-TOPO TA expression
vector. After the sequence of these plasmids was checked, they
were transfected into 293T epithelial cells and Mel501 melanoma
cells, along with control plasmids encoding lacZ. Initial assessment
using MTT assays suggested that transfection of 293T cells with
the UBE2S expression plasmid caused a significant increase in cell
numbers after 2 and 4 days, relative to lacZ control plasmids and
untreated cells (Figure 8A, t-test p value #0.05). This is broadly
consistent with the role predicted for UBE2S by the gene network
as a positive regulator of many cell cycle children. In contrast,
transfection with the ELMOD1 and TMCO1 expression plasmids
caused a significant decrease in cell numbers relative to lacZ
controls and untreated cells in 293T cells (Figure 8B, t-test p value
#0.05), broadly consistent with the role predicted by the gene
network as a positive regulator of many children associated with
apoptosis. Transfection with the ELMOD1 and TMCO1 expression
plasmids into Mel501 melanoma cells also caused a trend towards
decrease in cell numbers relative to lacZ controls and untreated
cells in 293T cells, however this was not statistically significant
(Figure 8C, t-test p values =0.08 and 0.13 at 2 and 4 days,
respectively).
In the course of our work we learned that UBE2S had already
been characterised under another name [60]. This characterisa-
tion concurred with our own overexpression-MTS experiment,
and showed that UBE2S increased the rate of the cell cycle by
targeting and degrading the von Hippel-Lindau protein. There-
fore, we did not follow UBE2S further in the laboratory. We
studied the effect of transfection of lacZ control, ELMOD1 and
TMCO1 expression plasmids on the cell cycle by flow cytometry of
propidium iodine-stained cells. In both 293T cells (data not shown)
of the box the interquartile range. Panels A and B include all RNAs on the microarrays that have the specified GO annotations. Panels C and D include
the Bayesian network hub RNAs, for which the function of downstream gene network children is significantly enriched for the specified GO
annotations. Panels A and C represent primary tumours [58] while panels B and D represent metastatic tumours [57].
doi:10.1371/journal.pone.0034247.g006
Figure 7. The edges immediately downstream of gene network
hubs that were enriched for cell cycle-associated children. Each
red dot represents a probe set of either a gene network hub that has
significant cell cycle enrichment of children, or one of the children. Blue
lines represent gene network edges.
doi:10.1371/journal.pone.0034247.g007
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PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e34247and Mel501 cells (Figure 8D), transfection of the ELMOD1 and
TMCO1 expression plasmids had no obvious effect on the
proportion of cells with 2N and 4N DNA content, but it did
substantially increase the proportion of cells with degraded DNA
in the hypodiploid peak, consistent with the induction of apoptosis.
293T cells transfected with lacZ control, ELMOD1 and TMCO1
expression plasmids were then analysed by Western blotting with
an antibody raised against the caspase-3 target PARP, which
showed PARP cleavage in the cells transfected with the ELMOD1
and TMCO1 expression plasmids but not in the cells transfected
with the control expression plasmid. Transfection of 293T cells
with GFP-tagged ELMOD1 and TMCO1 expression plasmids using
the pIRESeGFPII backbone indicated that the overexpressed
proteins localise in structures within the cytoplasm (Figure 8E).
The expression levels of UBE2S and TMC01 but not ELMOD1
RNA in metastatic melanomas appear to be significantly
associated with the survival of patients (Figure 8G–I).
In summary, three relatively uncharacterised genes, which the
gene networks predicted would influence the abundance of
apoptosis-associated or cell cycle-associated RNAs, were found
to alter apoptosis and cell number when overexpressed in vitro. The
expression levels in metastatic melanoma tumours of two of these
genes (UBE2S and TMCO1) appear to be significantly associated
with the time to relapse in melanoma patients.
Discussion
Meta-analysis of melanoma microarray studies
RNA signatures from melanoma microarray studies have
provided useful information about many aspects of the biology
of this tumour type (see the papers summarised in Table 1).
Therefore, at the start of this study we attempted a meta-analysis
of published microarray data related to melanoma progression,
metastasis and prognosis, hoping to identify consistent gene signatures
for these clinical features. However, we found there was very little
concordance between the different studies, despite the fact they
appeared to have been carried out to a high standard. We noted
that each of the published studies contained different patient
groups, different tumour sites, and different histopathological
tumour types. These differences may be in part responsible for the
distinct gene signatures produced by the different microarray
studies. A recently published review of melanoma microarray
studies [61] has reached similar conclusions about discordance
between melanoma microarray studies.
siRNA-treated A375 cells appear to model some but not
all transcriptional relationships present in melanoma
tumours
Given the diversity of melanomas in patients discussed above,
we proposed that rather than perform a meta-analysis of patient
tumours, a more effective way to obtain new insights into
melanoma biology could be to generate a microarray dataset in
A375 cells, in which transcription factors and signalling molecules
were targeted using siRNAs. We hoped that this approach would
generate a dataset with controlled differences between siRNA-
treated cultures, to increase our sensitivity for revealing meaning-
ful molecular pathways. Similar approaches have been used
successfully in other cancers to understand oncogenic signalling
pathways. For example, Bild et al. transfected cultures of quiescent
primary mammary epithelial cells with specific oncogenes and
performed microarray analysis to identify clinically relevant
oncogenic pathways in breast cancer [62], and the connectivity
map project [63] also takes the approach of deeply studying cancer
cell lines placed into in a large number of different ‘‘states’’ in vitro.
The dataset produced by this experiment was analysed using
whole genome Bayesian networks, and since this method is
relatively new, in parallel using a simple hierarchical clustering
method. Reassuringly, both methods identified similar co-
expression clusters. It was interesting that eleven of the molecules
previously implicated in melanoma pathogenesis (described in the
introduction) were identified as hubs in the Bayesian gene
networks generated from our A375 cell dataset, including: BRAF,
CCND1, RB1, PTEN, TYR, CDKN2A, and SOX10. However, the
interactions between these molecules that are known experimen-
tally (at the level of either transcription or post-translational
signalling) were in general not identified by the gene networks. It is
possible that these interactions simply do not operate in cultured
A375 cells, or that the 45 siRNA disruptions used in this study did
not introduce sufficient variability in the expression of these
molecules to allow latent relationships between them to be
identified.
Like all in vitro cell work, our use of A375 cells, cultured in the
laboratory potentially comes at the cost of losing biological
validity. To assess the similarity between A375 cells and
melanomas in patients at a transcriptional pathway level, we
compared the RNA correlations within biologically-relevant gene
sets identified across A375 cells with those identified across both
primary and metastatic melanomas. We found that several gene
sets (e.g. those related to the cell cycle) were approximately
equivalently correlated across both the A375 cells and the clinical
data. We identified other gene sets that were more frequently
correlated in the clinical microarray data than in the A375 cell
data, such as gene sets associated with immune response. Immune
response plays a major role in melanoma biology [64] and has
prognostic implications for melanoma patients [57,65] and, as
described in the introduction, therapies that modify immune
pathways in melanoma hold great promise for a subset of
melanoma patients. However, the fact that the transcriptional
pathways associated with melanoma immune response and
inflammation are not apparent in our A375 cell data limits our
Figure 8. Laboratory investigation of gene network hubs. A–C, general cell biological effects of plasmid over-expression. Human 293T
embryonic kidney cells (A and B) and human Mel501 melanoma cells (C) were transfected with control plasmids encoding lacZ and with plasmids
encoding UBE2S (A), ELMOD1 (B and C) and TMCO1 (B and C). At 0, 2 and 4 days after the transfection, the number of viable cells was assessed using
MTT assays. X-axes represent time in days while y-axis represent the OD570 absorbance (indicating viable cell number). Error bars represent standard
deviation of the mean from four replicate wells. All graphs are representative of at least three independent experiments. D, Cell cycle analysis.
48 hours after transfection of plasmids into Mel501 cells, the cells were analysed by flow cytometry to identify the % cells in different phases of the
cell cycle. Numbers show the percentage of hypodiploid cells. E, Fluorescent microscopy suggests that GFP-tagged over-expressed Elmod1 and
TMC01 proteins have a punctate cytoplasmic distribution. F Western blotting indicates PARP cleavage in cells transfected by Elmod1 and TMC01
plasmids. 48 h after transfection of Mel501 melanoma cells with Elmod1 and TMC01 plasmids, protein lysates were analysed by Western blot using
anti-b-actin and anti-PARP (a Caspase target degraded during apoptosis) antibodies. G–I, survival analysis in metastatic melanoma. Graphs compare
survival of patients whose metastatic melanomas had above (green) or below (red) the 50
th percentile of the particular RNA expression in the
Bogunovic 2009 data series [57]. All experimental data shown in panels A–F of this figure are representative of at least three independent
experiments.
doi:10.1371/journal.pone.0034247.g008
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in vitro. This limitation is not surprising, given that the immune
cells that participate in these pathways in tumours are absent from
the A375 cell cultures. Other gene sets that were more frequently
correlated in the clinical microarray data than in the A375 cell
data include heparin sulphate proteoglycan synthesis and amino
acid acetylation, as well as targets of the transcription factors
MYC/MAX, POU3F2 and GCNF. It is possible that these
processes/transcription factors are highly active in tumour stromal
cells, and therefore are not identifiable in cultured A375 cells.
Hub genes are predicted by the Bayesian gene network to be
regulators of the expression of their children. Experimental
evaluation of the directional gene expression relationships between
gene network parents and their children is beyond the scope of this
study. Nevertheless, we followed up three hubs from the A375 cell
gene networks that were not well characterised. These were chosen
based on the enrichment of their downstream network children for
functions (cell cycle and apoptosis) that could be easily examined in
our laboratory and that were clinically relevant. It was encouraging
that in the pilot experiments presented here, overexpression of
RNAs encoding these hubs appeared to alter the specific functions
associated with hub children. Further studies are now needed to
confirm the levels of plasmid expression achieved and to define the
mechanisms by which hub overexpression alters cell biology.
Associations between the abundance of genes
highlighted by the A375 gene networks and patient
survival
We found that in metastatic tumours, the abundance of gene
network hub RNAs enriched for children with cell cycle and DNA
repair functions, but not several other functions, were frequently
associatedwithpatientsurvival.Someofthehubgenesweidentified
had previously been associated with survival in the original
Bogunovic et al. study of this dataset [57]. These findings fit well
with the known role of cell proliferation pathways in melanoma
progression. For example, mitotic incidence is the second most
powerful prognostic factor after thickness for primary melanoma
[66], and many of the inherited melanoma predisposition genes
encodeproteinsinvolvedinthecellcycle(seeIntroduction).Thecell
cycle clusters identified by the gene network, and the hubs that are
predicted by the network to drive the expression of these clusters,
may in the future assist selection of biomarkers for the prognosis of
metastatic melanoma lesions, to supplement the assessment of
histological grade as a prognostic indicator.
Our choice of the 45 siRNAs transfected into the A375 cells was
in fact biased towards RNAs encoding proteins with specific
functions. The GO database indicated that of the 45 siRNAs used,
21 were associated with regulation of the cell cycle (GO:0000074),
22 with regulation of transcription (GO:0045449), and 24 with
regulation of metabolism (GO:0019222). Since gene network
inference depends upon variation in gene expression between the
siRNA-targeted cell cultures, large numbers of siRNAs related to
proliferation may have increased the resolution of our gene
networks for proliferation-associated transcriptional pathways, and
therefore contributed to our identification of survival-associated
cell cycle clusters. However, the effect of siRNA choice on gene
network results may be complex, since we did not see dominant
network clusters associated with the functions of metabolism and
transcription, for which our siRNA set was also enriched. We are
unsure why no strong relationship was seen between abundance of
hub RNAs enriched for children with cell cycle functions and
patient survival in the primary tumour data [58]. It is possible that
the effect of cell cycle pathways on tumour biology is only
significant in metastatic tumours. However, this seems unlikely
since our supervised clustering analysis (Figure 5) showed similar
correlations of cell cycle-associated gene sets in primary and
metastatic melanomas. To clarify this issue, annotation of other
previously published Affymetrix studies of primary melanomas
with patient survival data would be useful.
Given the clear association between cell proliferation transcrip-
tional modules identified in this study and patient prognosis, these
modules have potential clinical usefulness. For example, an 8-gene
classifier developed from Bayesian gene network hubs correctly
classified the prognosis of 23/26 metastatic melanoma patients in
a pilot cross-validation study (Figure S1). While this is very
encouraging, given the very small number of patients that could be
used for this class prediction, and the cross-validation strategy that
therefore had to be employed, further studies using large
independent test sets are now needed to validate this classifier.
As another potential use, gene expression modules associated with
specific drug targets may provide biomarkers to allow patient
stratification. For example, the cell cycle-associated gene network
hub TYMS is a target of 5-fluorouracil, a drug that has been
studied in melanoma in the past [67] but has not proved generally
successful in melanoma patient populations. It is possible that
those melanoma patients with high expression of RNAs that are
clustered with/downstream of TYMS in our analysis, indicating
active molecular pathways involving TYMS, may be better
candidates for topical 5-fluorouracil treatment than other patients.
Assessment of the effects of cross-hybridisation
Asdescribedinthemethods,weshowedthat,foroneclusterofco-
regulated RNAs in the A375 melanoma cell dataset, the highly
correlated gene pairs were not conserved in a similar dataset
generated in MCF-7 breast cancer cells (Figure S2A). This analysis
was then repeated for all probe sets (Figure S2B and S2C). This
implies that cell type-specific transcriptional pathways, and not
cross-hybridisation, are the dominant driver of the RNA-to-RNA
relationships on which this study was based. However, the extent of
cross-hybridisation in Affymetrix data remains an area of debate,
withsomeresearcherssuggestingthatcross-hybridisationmaycause
problems for correlation-based analysis of microarray data [68],
whileothersconcludethatthisisnotthecase,andthat‘‘theobserved
long-rangecorrelationsinmicroarraydataareofabiologicalnature
rather than a technological flaw’’ [69]. Our data supports this latter
view, although further studies may be needed to address this issue
fully. Cross-hybridisation will not be an issue when the techniques
described here are applied to RNAseq data.
Conclusion
In this study, we used siRNAs to knock down the abundance of
45 functionally important mRNAs in A375 melanoma cells. A
variety of methods were then used to reverse engineer co-
expression clusters and gene networks from this data. We
identified several gene sets that were correlated both across
siRNA-treated A375 cells and across melanomas from patients (e.g.
gene sets associated with the cell cycle), as well as other gene sets
that were correlated only across the clinical melanomas (e.g. gene
sets associated with immune function). Several clusters enriched
for cell cycle functions and the hubs upstream of these clusters in
the gene networks were significantly associated with patient
survival, suggesting new prognostic biomarkers, and underlining
the importance of the transcriptional pathways that control the cell
cycle for melanoma biology. Our analysis also illustrated the
frequent co-expression of functionally-related RNAs. We hope
that bioinformatic methods like those used here can work
alongside traditional tumour biology studies to improve our
understanding of melanoma and to derive new biomarkers and
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addition, we hope that the methods described here for estimating
the correlation of genes that share the same biological functions
will be useful to estimate the validity of cell culture models for
specific aspects of other human diseases.
Materials and Methods
Cell culture and transfection
A375 melanoma cells [70] and HEK293T (293T) embryonic
kidney epithelial cells were obtained from the American Type
Culture Collection (ATCC, Manassas, USA). Mel501 cells [71]
were provided by Dr Ruth Halaban (Yale University School of
Medicine, New Haven, CT). A375 cells were chosen for the in vitro
functional genomics experiments described here since their
transcriptome appears to be moderately representative of clinical
melanoma tumours; for example they are positioned close to
several tumours in a multidimensional scaling analysis [31]. A375
and 293T cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% foetal calf serum.
Mel501 cells were cultured in opti-MEM medium (Invitrogen,
Carlsbad, USA) supplemented with 7% foetal calf serum. All cells
were maintained at 37uC in a fully humidified atmosphere
containing 5% CO2. For transfection with siRNAs (20 nM final
concentration, Dharmacon siGenome Smartpools, Dharmacon,
Lafayette, USA) cells were seeded in 6-well plates, and the
following day when cell density had reached 30% confluence, cells
were washed and media replaced with 1 mL of opti-MEM
containing 30 ml Oligofectamine (Invitrogen, Carlsbad, USA) and
10 nM siRNA duplexes. 48 hours after transfection cells were
harvested using TRIzol (Invitrogen, Carlsbad, USA) and RNA
extracted using the RNeasy RNA Extraction system according to
the manufacturer’s instructions (Qiagen, Hilden, Germany). The
45 siRNA transfections into A375 cells were performed in three
experimental batches. RNA quality was confirmed using an
Agilent 2100 bioanalyser. For transfection with plasmids, the same
procedure was followed except that 5 ul Lipofectamine 2000
reagent (Invitrogen, Carlsbad, USA) and 2 ug plasmid were mixed
in 1 mL opti-MEM medium and incubated at room temperature
for 15 min before being added to the washed cells for 48 hours.
Microarray analysis and data processing
Biotin-labelled cRNA was generated and hybridised to
Affymetrix Human Genome U133plus 2.0 microarrays following
the manufacturer’s instructions (Affymetrix, Santa Clara, USA).
All microarray data used in this manuscript is MIAME compliant
and has been deposited in GEO. The GEO accession number for
microarray data from siRNA-treated A375 cells is GSE31534.
The GEO accession number for microarray data from siRNA-
treated MCF-7 cells is GSE 31912. Array analysis was performed
using the statistical framework ‘R’ (http://cran.r-project.org/). All
microarrays passed quality control using the ‘AffyQCreport’ R
package. Microarray ‘CEL’ files from the siRNA-treated A375
cells, and from previously published studies, were normalised using
the Robust Multichip Averaging (RMA) algorithm [72] provided
by the R ‘affy’ package. To remove any possible batch effects we
scaled each probe set based on its median expression in each
experimental batch. Gene lists were tested for enrichment of
particular functional categories using the GATHER web tool [49],
as well as using the Ingenuity Pathways Analysis (IPA) software
(http://www.ingenuity.com/).
Spearman rank correlation coefficients, which are based on the
correlations between the ranks of variables, were generated using
the ‘cor’ function in the R base package. Whole-genome Bayesian
gene networks were reverse engineered from the siRNA-treated
A375 cell microarray data by estimating large numbers of sub-
networks in parallel that were later amalgamated, as described
[47], using massively parallel supercomputers at the Tokyo
University Human Genome Center. Kaplan-Meier survival
analysis with both log-rank significance tests and significance tests
using Cox proportional hazards models were performed using the
R ‘survival’ package (http://cran.r-project.org/web/packages/
survival/). Class prediction was performed using shrunken
centroid classifiers with the ‘‘pamr’’ R package [59].
Meta-analysis of published melanoma microarray
datasets
For all ‘‘cel’’ files quality control was performed using the
‘AffyQCReport’ package [73] in R. Re-normalisation of all arrays
together was in all cases performed from raw data in.cel files using
the RMA method with background correction, and differential
expression was analysed using LIMMA (Linear Models for
Microarray Data) [74]. The ‘‘metaMA’’ package in R [75] was
used to perform statistical meta-analysis. The GATHER web tool
[49] was used to identify whether any lists of differentially
expressed RNAs were enriched for the targets of specific
transcription factors (using the TRANSFAC Pro database v8.0,
[50]), or for molecules with a common function (the Gene
Ontology (GO) database, [51]). The PCOT2 multivariate analysis
method in R [42] was also used to identify correlated differential
expression KEGG gene sets [76]. When composite data sets were
generated from multiple published melanoma microarray studies,
to remove study cohort effects we scaled each probe set based on
its median expression in each study.
Hierarchical clustering
All 54,000 probe sets on the A375 cell microarrays were
hierarchically clustered using Ward’s method [77] with dissimi-
larities between observations calculated using 12|r| to allow
positively and negatively correlated genes to be included in the
same cluster. Clusters were chosen so that: cluster size was .5
probe sets, the minimum correlation between any two probe sets
within a cluster was $0.4, and the median correlation of all
possible combinations of the members of each cluster was $0.5.
The 200 clusters selected contained in total 1,753 probe sets; 35%
of the clusters contained 5–10 probe sets, 9% contained 10–20
probe sets, with 13 clusters containing $30 probe sets. For over-
representation analysis using the GATHER web tool, significant
enrichment of cluster members was said to have occurred when:
Bayes Factor$5 and permutation p#0.05. For this descriptive
investigation of the A375 cell data, the cutting of the dendrogram
into 200 clusters and the parameters used for cluster membership
filtering were arbitrary choices. However, trials using different
cluster numbers and parameters for cluster filtering did not
produce clusters that were significantly enriched for any additional
gene sets. When we repeated this clustering using only those probe
sets with median expression of $1.5x the 39 BioB probe set (a
probe set that can be used as an indicator of the noise threshold),
five clusters associated with the cell cycle and seven associated with
transcription factor targets were identified but no additional GO
paths or transcription factor motifs for which clusters were
enriched were identified.
Evaluation of cross-hybridisation artefacts
It has been suggested that a fraction of the probe sets in
Affymetrix microarrays may cross-hybridise with multiple mRNA
transcripts, which could lead to spurious clustering and gene
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correlation coefficients between all possible combinations of probe
sets from the cluster shown in Figure 3 across: (i) our A375 siRNA
Affymetrix Human Genome U133 plus 2.0 dataset and (ii) an
unpublished Affymetrix Human Genome U133 plus 2.0 dataset
from our laboratory, in which we have used a set of 70 siRNAs to
target MCF-7 breast cancer cells. Given that the identical
microarray platform was used in the A375 and MCF-7 siRNA
datasets, if cross-hybridisation was the dominant driver of the
clustering observed in the A375 cells, then we would expect to see
similarly high correlations between the same probe sets in the
MCF-7 cells. In fact, we found that the high correlations observed
between probe sets in the A375 cells were largely absent from the
MCF-7 data (Figure S2A). We then repeated this on a whole-
genome scale, by calculating the Spearman’s r in the MCF-7 data
for the 54,681 probe set pairs that had Spearman’s |r|$0.8 in the
A375 data (Figure S2B), and by calculating the Spearman’s r in
the A375 data for the 184,911 probe set pairs that had Spearman’s
|r|$0.8 in the MCF-7 data (Figure S2C). These analyses
suggested that Affymetrix Human Genome U133 plus 2.0
microarray probe set pairs that were highly correlated in data
from A375 cells were in general not highly correlated in data using
the same microarray platform from MCF-7 cells and vice versa,
suggesting that cross-hybridisation between Affymetrix probe sets
was not the most significant driver of the clustering we observed
across the A375 dataset.
Whole genome Bayesian gene network analysis
This was carried out using massively parallel supercomputers at
Human Genome Center of the University of Tokyo as previously
described [45]. In brief, this method uses a heuristic algorithm
called the neighbor node sampling & repeat (NNSR) method to estimate
100,000 overlapping small sub-networks selected from the
intermediate global network structure, which is improved by the
estimated sub-networks during the method. Edges that were
present in at least 20% of these sub-networks were combined into
a final 1,645,882 edge gene network for analysis (can be
downloaded, with a brief explanatory file, from http://www.
bioinformatics.auckland.ac.nz/doc/project_data/Supplementary_
FIle_1.txt).
To illustrate the information underlying this network, Figure S3
explores the relationships between those gene network parents that
were targeted by siRNA when generating the data set from which
the gene networks were inferred, and their 1,800 gene network
children. Although this analysis was by necessity performed on the
same data set from which networks were inferred, the Bayesian
gene network inference method used does not utilise information
about the effects of the siRNA treatments on individual probe sets.
Correlations between these parents and their children are
significantly larger then correlations between randomly chosen
nodes (Figure S3A). These children show a trend to be down-
regulated by parent knockdown when parent and child correlate
positively across the dataset, and to be up-regulated by parent
knockdown when parent and child correlate negatively (Figur-
e S3B–D). The regulation of child abundance after parent
knockdown was generally small in magnitude, consistent with
the expected dilution of the effect of knocking down any single
parent by the undiminished effects of the remaining parents that
were not knocked down. This Bayesian network method was
primarily used in this study to identify co-expressed clusters rather
that directional regulation. Future experimental evaluation of
directional network predictions will be interesting but this is
beyond the scope of this study.
Cloning
Coding regions were amplified using Platinum Taq DNA
Polymerase (Invitrogen, Carlsbad, USA) from cDNA that had
been reverse transcribed from A375 cell RNA, then cloned
directly into the pcDNA3.3-TOPO-TA expression vector. Liga-
tion products were used to transform One-shot Top10 competent
cells (Invitrogen, Carlsbad, USA) and colonies selected by PCR
using gene-specific primers. Plasmid DNA was extracted using a
Zyppy Plasmid Miniprep Kit (Zymo, Orange, USA) and the
inserts sequenced on both strands. Plasmids for transfection were
prepared using a QIAGEN endo-free Plasmid Maxi Kit according
to the manufacturer’s instructions (Qiagen, Hilden, Germany).
The oligonucleotide primers used for cloning are described in
Table 4.
Analysis of culture growth, the cell cycle and apoptosis
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) colorimetric assays were used to estimate viable cell
number according to the manufacturers instructions (Invitrogen,
Carlsbad, USA). Briefly, A375, Mel501 and 293T cells were
seeded in 96-well plates at 3,000, 6,000 and 12,000 cells/well
respectively. 10 ml of MTT (5 mg/ml) was added into each well;
after 4 h incubation at 37uC 100ml of lysis buffer was added and
plates were incubated at 37uC overnight. The next day the plates
were read at OD570. Each condition was analysed in six replicate
wells and all experiments were repeated at least three times.
For cell cycle analysis, cells in each well of a 6-well plate were
trypsinised, washed three times by ice cold PBS then fixed in 3 ml
of 70% ethanol in PBS added dropwise while vortexing. Cells were
stained with 50 mg/ml propidium iodine (PI), 0.1 mg/ml RNase
A, 0.05% (v/v) Triton X-100 at 37uC for 40 min then assayed by
Flow Cytometry, with the results analysed using ModFit LT
software (Verity, Topsham, USA) according to the manufacturer’s
instructions. All cell cycle analysis experiments were repeated at
least three times.
For Western blotting to identify caspase activation during
apoptosis, cells were trypsinised and washed three times with ice
cold PBS, then pellets were mixed with lysis buffer (50 mM
Tris.NaCl, 150 mM Na.Cl, 1% (v/v) Triton X-100, 1 mM
EDTA, 1 mM EGTA and 1% (v/v) Protease Inhibitor Cocktail
(‘‘Complete’’, Roche, Basel, Switzerland)) and incubated for
30 min on ice. Lysates were then micro-centrifuged at 4uCa t
13,000 rpm for 15 min then 20 mg loaded into each well of 10%
SDS-PAGE gels, separated, then transferred to BioTrace NT
nitrocellulose membranes (PALL, Port Washington, USA).
Membranes were blocked for 2 h at room temperature in blocking
buffer (Tris-buffered saline containing 1% (v/v) Tween-20 and 5%
(w/v) skim milk powder) and then incubated with anti-Poly ADP-
ribose polymerase (PARP) antibody (Cell Signalling Technology,
Table 4. Primers.
Primer
orientation
RNA
target Sequence (59 to 39)
forward ELMOD1 CACCATGAAGCACTTCCTGAGAATG
reverse ELMOD1 GGATCCCTACATGTTGATTAAACCTTCCG
forward UBE2S CACCATGAACTCCAACGTGGAGAAC
reverse UBE2S TCACGGTGGAAGGAGGAA
forward TMCO1 CACCATGAGCACTATGTTCGCGG
reverse TMCO1 TCAAGAGAACTTCCCAGAAGGA
doi:10.1371/journal.pone.0034247.t004
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were washed in blocking buffer and incubated with goat anti-
rabbit IgG–peroxidase antibody, washed three times in blocking
buffer, then incubated with ECL plus reagents (GE healthcare,
Pittsburgh, USA) for 5 min before scanning. All PARP Western
blotting experiments were repeated at least three times.
Supporting Information
Figure S1 Class prediction based on the gene network
hub probe sets. (A) Shrunken centroid classifiers were
developed and assessed by cross-validation using eight gene
network hub probe sets. (B) For these eight probe sets, the
normalised expression signals in metastatic melanoma tumours
from the Bogunovic et al. (2009 [57]) dataset (y-axis) are plotted
across the 26 tumours (x-axis). Green represents patients who died
before 2 yrs and red patients who lived beyond 3 yrs.
(TIF)
Figure S2 Affymetrix probe set-to-probe set correla-
tions are not conserved between cell types. (A) The kernel
density plot shows the distribution of Spearman’s correlation
coefficients between all members of an E2F1-associated A375 cell-
derived cluster (which was shown in Figure 3) in the A375 cell data
(red) and in a similar MCF-7 cell dataset (green). (B) Spearman’s
correlation coefficients were calculated in the MCF-7 data (green)
for the 54,681 probe set pairs that had |Spearman’s correlation
coefficients| $0.8 in the A375 data (red). Spearman’s correlation
coefficients were calculated in the A375 data (red) for the 184,911
probe set pairs that had |Spearman’s correlation coefficients|
$0.8 in the MCF-7 data (green).
(TIF)
Figure S3 Relationships between gene network parents
that were targeted by siRNA and their gene network
children. (A) The distribution of Spearman’s correlation
coefficients between parents that were targeted by siRNAs and
their 1,800 gene network children is shown in red. The
distribution of Spearman’s correlation coefficients between ten
randomly chosen sets of 1,800 genes is shown in grey as a control.
(B) For each of the 1,800 gene network children shown in A, the
ratio of (expression after siRNA knockdown of the parent) to
(median expression across all microarrays) was calculated. This
ratio will always be ,=21o r.=1). For all 1,800 parent-child
edges, this ratio (y-axis) was plotted against Spearman’s correlation
(x-axis). This shows a trend for the gene network children of
parents targeted by siRNAs to be down-regulated after parent
knockdown when parent and child correlate positively, and to be
up-regulated after parent knockdown when parent and child
correlate negatively. C and D show the distributions of fold change
after parent knockdown for those network edges where parent and
child were positively and negatively correlated, respectively.
(TIF)
Table S1 The hubs in the Bayesian network with
children significantly enriched (Bayes Factor $5 and
p#0.05) for functions related to cell cycle, mitosis or
proliferation. Hub probe ID and hub official gene symbol
(OGS) are given in the first two columns. The GATHER Bayes
Factor and the probability of obtaining this Bayes factor due to
chance are shown in columns 4 and 5. Column 6 lists the children
of the gene network hub that have the enriched annotation listed
in column 3. Column 7 shows the Cox proportional hazards
(coxPH) survival p-value for the association of hub RNA
abundance in metastatic tumours with patient survival, with those
hubs with p-values #0.05 highlighted in yellow.
(XLSX)
Table S2 A375 Bayesian network hubs that have
children significantly enriched for cell cycle functions.
Affymetrix probe set ID (parent probe ID) and official gene symbol
(parent OGS) are shown in columns 1 and 2. The number of
children of these hubs in theA375 Bayesian gene network is shown
in column 3. Of these children, the number and % that have
|Spearman’s r| $0.4 with their parents are shown in columns 4
and 5, respectively.
(XLSX)
Table S3 Conserved correlations between the hub DTL
(probe ID 222680_s_at) and its children between the
A375 in vitro siRNA dataset and metastatic tumours in
patients of the Bogunovic study. The gene network parent
(222680_s_at) and gene network child probe set ID and OGS are
given in the first 4 column. Column 5 shows the |Spearman’s r|
between the parent and child across the A375 siRNA dataset,
while column 6 shows the |Spearman’s r| between the parent and
child across the Bogunovic metastatic tumour dataset. In columns
5 and 6 |Spearman’s r| $0.4 are highlighted in orange. Columns
7 and 8 show the Cox proportional hazards p-value for association
between probe set abundance in metastatic tumours and patient
survival for parent and child, respectively. In columns 7 and 8
p#0.05 are highlighted in green. (Note that the presence of some
gene network edges with relatively low |correlation coefficients|,
as seen here, is expected in Bayesian gene networks due to some
network edges having high partial residual correlations even
though they have low correlations across the data.
(XLSX)
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